Our fortnightly newsletter provides unparalleled data, insights and intelligence on the global psychedelics industry, straight to your inbox. Find the latest commercial deals, understand the latest regulatory changes and discover the most impactful scientific discoveries. Subscribe for free now.
Following a breakout year for the psychedelic sector, the pharmaceutical industry is set to take on a more prominent role in the market in 2021 and beyond. Learn more and catch up with the latest investment trends and scientific findings in Issue 13 of The Psychedelics Newsletter.
The psychedelic compound known as DMT will be used in a trial to treat depression for the first time in the United Kingdom while MDMA has been proven to help people suffering from alcohol addiction. All this and more in issue 12 of the PSYCH Newsletter.
Gain access to every panel discussion from The PSYCH Symposium before time runs out and catch up on the latest news from across the international psychedelics industry in Issue 11 of The Psychedelics Newsletter, here.
A petition to legalise natural psychedelics in Canada reaches 13,000 signatures, and a Congressman has said psychedelics show promise in treating PTSD as Oakland activists also unveil guidelines for psychedelic healing ceremonies.
Canada approves end-of-life psilocybin treatment for palliative patients while UK scientists and experts propose easing restrictions for medical psychedelics and Californian activists propose easing restrictions for medical psychedelics.
An attempt to block the Washington D.C. psychedelic initiative fails, therapists request approval to test psychedelics in Canada and Oregon gets set to vote on psilocybin for therapeutic use in November 2020.
Oregon psilocybin decriminalisation campaign and DC activists say they will qualify for the November ballot while the New Medical Psychedelics Working Group to lobby for ease in UK research restrictions.
THE LATEST INSIGHTS, STRAIGHT TO YOUR INBOX
Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.
+44 (0) 203 928 2814
20-22 Wenlock Road, London, N1 7GU, United Kingdom